BridgeBio Pharma Secures up to $1.25 Billion of Capital from Blue Owl and CPP Investments to Accelerate the Development and Launch of Genetic Medicines
Amount Raised
$1.25 Billion
Round Type
Venture
Palo AltoBiotechnologyHealth CareTherapeuticsInvestors
Description
BridgeBio Pharma, Inc. secures up to $1.25 billion of capital from Blue Owl and CPP Investments to accelerate the development and launch of genetic medicines, including a $500 million cash raise, a $450 million credit facility, and the possibility of additional incremental facilities of up to $300 million of credit to support strategic pipeline expansion and acceleration. The financing allows BridgeBio to enter 2024 well capitalized to launch acoramidis and continue to accelerate its industry-leading genetic medicine R&D engine.
Who to call at BridgeBio, and when
A new round usually means BridgeBio is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day BridgeBio raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at BridgeBio, from your own LinkedIn network
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment BridgeBio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
BridgeBio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.